Some patients have been self-administering incorrect doses of semaglutide, the active ingredient in popular weight-loss and Type 2 diabetes drugs Wegovy and Ozempic, and overdoses may be related to “adverse events, some requiring hospitalization” reported to the U.S. Food and Drug Administration (FDA), the agency warned in a July 26 alert.
In some cases, patients took five to 20 times the prescribed dose, according to the alert. These patients administered compounded versions of the drug from compound pharmacies rather than drug manufacturers, the FDA said.
